Xafinact 50mg

Use in patients with severe hepatic impairment, albinism (lack of pigment in the skin and eye), uveitis (inflammation inside the eye), retinal degeneration, inherited retinopathy, or severe diabetic retinopathy is contraindicated. Concomitant treatment with pethidine and other monoamine oxidase inhibitors is contraindicated. The antiparkinsonian drug should not be given to patients with severe hepatic impairment. Xafinact is contraindicated in patients with a history of safinamide. Reactions have included swelling of the tongue and oral mucosa. Due to insufficient evidence, the medicine is not recommended for children and adolescents below 18.     

Common side effects include headache, insomnia, feeling sleepy, trouble performing voluntary movements, clouding of the eye's lens, nausea, falling, and falls in blood pressure when rising to a standing position and worsening of Parkinson’s disease. These side effects have been associated with the use of Safinamide formulation. Inform your doctor if any of these bothers or persist for longer. 

Xafinact, 50 mg tablets, are for oral use. These should be taken with water. One may take the tablet before or after consuming food. Take the dosage as prescribed. Usually, the treatment starts from 50 mg per day. Based on the individual requirement, the dose may be increased to 100 mg daily after 14 days. In patients with moderate hepatic impairment, the maximum recommended dose is 50mg once per day. If a patient taking 50 mg of Safinamide progresses from moderate to severe liver insufficiency, discontinue the treatment.

Daily dosages above 100 mg have not been shown to provide additional benefits; higher doses only increase the risk of side effects. The medicine is effective only in combination with carbidopa/levodopa. Safinamide should be used during pregnancy only if the potential benefit justifies the risk to the fetus.